Summary Comments
- Most frequently detected viruses during April 2023 (all age groups):
- Rhino/Enterovirus: 31.8%
- Rhinovirus: 23.8%
- RSV A&B: 17.2%
- Epidemiological Week 1–18 Trends:
- SARS-CoV-2: Positive specimen rate ranged between 10.9% and 16.7%
- RSV: Peaked in week 11 at 32.2%, declined to 10% by week 18
- Influenza A: Increased sharply from week 16, reaching 20.8% in week 18
Respiratory Viral Multiplex PCR and SARS-CoV-2 PCR: All Age Groups
March 2023:
- Rhino/Enterovirus: 33.2%
- Rhinovirus: 23.9%
- RSV A&B: 29.7%
- SARS-CoV-2: 15.3%
- Influenza A: 4.4%
- Adenovirus: 4.6%
- Parainfluenza 1-4: 2.2%
- Metapneumovirus: 5.2%
- Coronavirus (non-SARS-CoV-2): 9.9%
- Influenza B: 0.1%
April 2023:
- Rhino/Enterovirus: 31.8%
- Rhinovirus: 23.8%
- RSV A&B: 17.2%
- SARS-CoV-2: 14.6%
- Influenza A: 10.1%
- Adenovirus: 3.3%
- Parainfluenza 1-4: 4.0%
- Metapneumovirus: 2.2%
- Coronavirus (non-SARS-CoV-2): 9.9%
- Influenza B: 0.1%
Weekly % Positivity: Weeks 1–18
SARS-CoV-2:
Peaked at 16.7% in week 10, decreased to 13.5% in week 18
Influenza A:
Peaked at 20.8% in week 18 (started rising in week 16)
RSV:
Peaked at 32.2% in week 11, declined to 10% in week 18
Atypical Bacterial Pathogens
Total Cases (Weeks 1–18):
- B. pertussis: 189
- B. parapertussis: 20
- M. pneumoniae: 363
Age Distribution – B. pertussis:
- 0–6 months: 26%
- 1–5 years: 24%
- 6–12 years: 22%
Age Distribution – M. pneumoniae:
- 1–5 years: 43%
- 6–12 years: 28%
Weekly Cases (Selected):
B. pertussis (weeks 1–18):
8, 7, 5, 16, 13, 4, 6, 8, 9, 9, 7, 11, 16, 10, 15, 19, 13, 13
B. parapertussis (weeks 1–18):
0, 1, 0, 2, 3, 2, 2, 1, 0, 1, 2, 2, 1, 0, 2, 0, 1, 0
M. pneumoniae (weeks 1–18):
4, 6, 10, 7, 5, 11, 12, 17, 12, 18, 25, 30, 23, 34, 37, 36, 34, 42
Paediatric Respiratory Viral Multiplex PCR Data (Ages 0–12)
<1 Year Age Group
March 2023:
- Rhino/Enterovirus: 37.7%
- Rhinovirus: 23.2%
- RSV A&B: 54.4%
- Metapneumovirus: 3.4%
- Parainfluenza 1-4: 3.5%
- Adenovirus: 6.6%
- SARS-CoV-2: 9.1%
- Influenza A: 0.8%
- Influenza B: 0.1%
April 2023:
- Rhino/Enterovirus: 42.0%
- Rhinovirus: 29.2%
- RSV A&B: 41.3%
- Metapneumovirus: 3.0%
- Parainfluenza 1-4: 5.0%
- Adenovirus: 4.5%
- SARS-CoV-2: 11.7%
- Influenza A: 2.3%
- Influenza B: 0%
1–5 Year Age Group
March 2023:
- Rhino/Enterovirus: 46.8%
- Rhinovirus: 34.4%
- RSV A&B: 40.8%
- Metapneumovirus: 4.3%
- Parainfluenza 1-4: 8.4%
- Adenovirus: 13.8%
- SARS-CoV-2: 16.0%
- Influenza A: 3.7%
- Influenza B: 0%
April 2023:
- Rhino/Enterovirus: 43.7%
- Rhinovirus: 36.6%
- RSV A&B: 23.0%
- Metapneumovirus: 3.1%
- Parainfluenza 1-4: 8.9%
- Adenovirus: 9.8%
- SARS-CoV-2: 17.3%
- Influenza A: 11.3%
- Influenza B: 0.2%
6–12 Year Age Group
March 2023:
- Rhino/Enterovirus: 26.7%
- Rhinovirus: 20.2%
- RSV A&B: 14.9%
- Metapneumovirus: 2.5%
- Parainfluenza 1-4: 1.2%
- Adenovirus: 5.4%
- SARS-CoV-2: 8.1%
- Influenza A: 13.1%
- Influenza B: 0.1%
April 2023:
- Rhino/Enterovirus: 32.0%
- Rhinovirus: 22.7%
- RSV A&B: 5.4%
- Metapneumovirus: 1.6%
- Parainfluenza 1-4: 2.4%
- Adenovirus: 1.9%
- SARS-CoV-2: 7.2%
- Influenza A: 17.7%
- Influenza B: 0%
Highlights by Age Group (April 2023):
- <1 year:
- RSV A&B: 41.3%
- Rhino/Enterovirus: 42.0%
- Rhinovirus: 29.2%
- 1–5 years:
- Rhino/Enterovirus: 43.7%
- Rhinovirus: 36.6%
- RSV A&B: 23.0%
- 6–12 years:
- Rhino/Enterovirus: 32.0%
- Rhinovirus: 22.7%
- Influenza A: 17.7%
Continue Reading